## Abstract The purpose of this study was to assess a new Gd‐based macromolecular intravascular contrast agent (P792, Vistarem®; Laboratoire Guerbet, Aulnay sous Bois, France) for MR angiography (MRA). P792 is a macrocyclic gadolinium compound based on a gadoterate meglumine structure substituted b
MR Angiography with a New Rapid Clearance Blood Pool Agent (P792)
✍ Scribed by Ruehm, Stefan G; Schmitz-Cristina, Heidi; Violas, Xavier; Corot, Claire; Debatin, Jörg F
- Book ID
- 123199723
- Publisher
- Elsevier Science
- Year
- 2002
- Tongue
- English
- Weight
- 29 KB
- Volume
- 9
- Category
- Article
- ISSN
- 1076-6332
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
An original MRI contrast agent, called P792, is described. P792 is a gadolinium macrocyclic compound based on a Gd-DOTA structure substituted by hydrophilic arms. The chemical structure of P792 has been optimized in order to provide (1) a high r 1 relaxivity in the clinical field for MRI: 29 mM -1 ×
## Abstract The signal‐enhancing characteristics of a new monodisperse monogadolinated macromolecular MR contrast medium (P792) were evaluated for magnetic resonance angiography (MRA) of the coronary arteries. A total of 15 cardiac examinations were performed in pigs at 1.5 T using a 3D gradient‐ec
## Abstract The diagnostic potential of a new rapid clearance blood pool contrast medium (P792; MW = 6.47 kDa) for the MR assessment of microvessel characteristics was assessed in 42 chemically‐induced breast tumors, with comparisons to albumin‐(Gd‐DTPA). Microvessel characteristics, including the
## Abstract ## Purpose To design an ideal first‐pass profile for MR angiography (MRA) by optimizing a multiphasic injection protocol based on two experimental animal models. ## Materials and Methods An equivalent contrast‐enhanced (CE) MRA injection protocol was developed with controlled injecti